{"title": "Protection against SARS-CoV-2 BA.4 and BA.5 subvariants via vaccination and natural infection: A modeling study", "author": "Yuta Okada; Taishi Kayano; Asami Anzai; Tong Zhang; Hiroshi Nishiura", "url": "http://www.aimspress.com/rticle/doi/10.3934/mbe.2023118", "hostname": "aimspress.com", "description": "With continuing emergence of new SARS-CoV-2 variants, understanding the proportion of the population protected against infection is crucial for public health risk assessment and decision-making and so that the general public can take preventive measures. We aimed to estimate the protection against symptomatic illness caused by SARS-CoV-2 Omicron variants BA.4 and BA.5 elicited by vaccination against and natural infection with other SARS-CoV-2 Omicron subvariants. We used a logistic model to define the protection rate against symptomatic infection caused by BA.1 and BA.2 as a function of neutralizing antibody titer values. Applying the quantified relationships to BA.4 and BA.5 using two different methods, the estimated protection rate against BA.4 and BA.5 was 11.3% (95% confidence interval [CI]: 0.01-25.4) (method 1) and 12.9% (95% CI: 8.8-18.0) (method 2) at 6 months after a second dose of BNT162b2 vaccine, 44.3% (95% CI: 20.0-59.3) (method 1) and 47.3% (95% CI: 34.1-60.6) (method 2) at 2 weeks after a third BNT162b2 dose, and 52.3% (95% CI: 25.1-69.2) (method 1) and 54.9% (95% CI: 37.6-71.4) (method 2) during the convalescent phase after infection with BA.1 and BA.2, respectively. Our study indicates that the protection rate against BA.4 and BA.5 are significantly lower compared with those against previous variants and may lead to substantial morbidity, and overall estimates were consistent with empirical reports. Our simple yet practical models enable prompt assessment of public health impacts posed by new SARS-CoV-2 variants using small sample-size neutralization titer data to support public health decisions in urgent situations.", "sitename": "Mathematical Biosciences and Engineering", "date": "2022-08-02", "cleaned_text": "| [1] || N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., A novel coronavirus from patients with pneumonia in China, 2019, New Engl. J. Med., 382 (2020), 727-733. https://doi.org/10.1056/NEJMoa2001017 || E. R. T. Gandhi, P. E. Sax, Transmission of SARS-CoV-2: A review of viral, host, and environmental factors, 174 69-79. Farkas, J. L. Domingo, SARS-CoV-2 and other pathogenic microorganisms in environment, C. Buckee, T. C.Smith, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission dynamics should inform policy, Clin. S170-S176. https://doi.org/10.1093/cid/ciaa1442 || D. Nash, M. S. Rane, M. M. Robertson, M. Chang, S. G. Kulkarni, R. Zimba, et al., SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults, Clin. Infect. doi: |[10.1101/2021.02.12.21251659](https://doi.org/10.1101/2021.02.12.21251659) | [6] || M. Coccia, Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral infectivity similar to COVID, Sci. Total. Environ., 729 doi: |[10.1016/j.scitotenv.2020.138474](https://doi.org/10.1016/j.scitotenv.2020.138474) | 2020 (with lockdowns) and 2021 (with vaccinations): similar effects for seasonality of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis, Environ. Res., | [9] || Coccia, Preparedness of countries to face COVID-19 pandemic crisis: Strategic positioning and factors supporting effective strategies of prevention of pandemic threats, Environ. Res., 203 Global analysis of timely COVID-19 vaccinations: Improving governance to reinforce response policies for pandemic crises, Int. J. Health Gov., 27 (2022), 240-253. https://doi.org/10.1108/IJHG-07-2021-0072 doi: |[10.1108/IJHG-07-2021-0072](https://doi.org/10.1108/IJHG-07-2021-0072) | [11] || L. Matrajt, J. Eaton, T. Leung, E. R. Brown, Vaccine optimization for COVID-19: Who to vaccinate W. Powell, Stochastic optimization for vaccine and testing kit allocation for the COVID-19 pandemic, Eur. J. Oper. Res., 304 (2023), 325-338. https://doi.org/10.1016/j.ejor.2021.11.007 doi: |[10.1016/j.ejor.2021.11.007](https://doi.org/10.1016/j.ejor.2021.11.007) | [13] || W. Cao, J. Zhu, X. Wang, X. Tong, Y. Tian, H. Dai, et al., Optimizing spatio-temporal allocation of the COVID-19 vaccine under different epidemiological landscapes, Front. Public Health, 10 Sroczynski, N. M\u00fchlberger, et al., An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply, 17 T. Leung, D. Dimitrov, J. T. Schiffer, D. A. Swan, et al., Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination, Nat. critical decisions in management, in Global Encyclopedia of Public Administration, Public Policy, and Governance, (2020), 1-10. |[https://doi.org/10.1007/978-3-319-31816-5_3969-1](https://doi.org/10.1007/978-3-319-31816-5_3969-1) | [17] || M. Coccia, Improving preparedness for next pandemics: Max level of COVID-19 vaccinations without social impositions to design effective health policy and avoid flawed democracies, Environ. Res., 213 Santra, G. S. Mahapatra, Global stability and analysing the sensitivity of parameters of a multiple-susceptible population model of SARS-CoV-2 emphasising vaccination Wang, F. Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, et al., mRNA vaccine-elicited antibodies to | [21] || Y. Liu, J. Liu, H. Xia, X. Zhang, C. R. Fontes-Garfias, K. A. Swanson, et al., Neutralizing activity of || R. Chen, X. Zhang, J. B. Case, E. S. Winkler, Y. Liu, L. A. VanBlargan, et al., Resistance of SARS-CoV-2 variants to neutralization by monoclonal and [23] || P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, et al., Antibody resistance of T. E. Schlub, A. K. Wheatley, J. A. Juno, et al., Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat. Med., 27 (2021), 1205-1211. https://doi.org/10.1038/s41591-021-01377-8 [25] || L. H. Kainulainen, N. Jiang, H. Di, G. Bonenfant, L. Mills, et al., Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by D. Eggink, C. van den Ende, N. van Maarseveen, L. Ali, et al., Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, et al., Covid-19 Vaccine effectiveness against the omicron (B.1.1.529) variant, N. Engl. M. Mandelboim, V. Indenbaum, S. Amit, et al., Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron, N. Engl. McGrath, T. R. O'Meara, S. Barman, J. Yu, H. Wan, et al., mRNA booster vaccination protects aged mice against the J. Miller, A. Y. Collier, J. D. Ventura, J. Yu, M. Rowe, et al., Neutralization Escape by SARS-CoV-2 Omicron Subvariants Y. Cao, A. Yisimayi, F. Jian, W. Song, T. Xiao, L. Wang, et al., BA.2.12.1, BA.4 and BA.5 escape antibodies elicited https://doi.org/10.1038/s41586-022-04980-y doi: S. Iketani, M. S. Nair, Z. Li, H. Mohri, et al., evasion by [33] || M. Huang, L. Wu, A. Zheng, Y. Xie, Q. He, X. Rong, et al., Atlas of currently-available human neutralizing antibodies against SARS-CoV-2 and Khan, Y. Ganga, M. Bernstein, Z. Jule, K. Reedoy, et al., Omicron BA.4/BA.5 escape neutralizing T. Zahra, D. Forgacs, H. Golding, T. M. Ross, et al., Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 [36] || Qin, P. B. Gilbert, L. Corey, M. J. McElrath, S. G. Self, A framework for assessing immunological correlates of protection in vaccine trials, J. Infect. Dis., 196 (2007), 1304-1312. https://doi.org/10.1086/522428 Gustafsson, P. Olin, Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis, Vaccine, 16 (1998), 1907-1916. https://doi.org/10.1016/S0264-410X(98)00227-8 doi: |[10.1016/S0264-410X(98)00227-8](https://doi.org/10.1016/S0264-410X(98)00227-8) | [38] || Y J. Yu, A. Y. Collier, M. Rowe, F. Mardas, J. D. Ventura, H. Wan, et al., Neutralization of the SARS-CoV-2 Omicron BA.1 and J. S. Adamson, B. R. M\u00e2sse, L. P. Garrison, J. G. Kublin, P. B. Gilbert, et al., Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study, Sci. Rep., 8 (2018), 1-12. https://doi.org/10.1038/s41598-018-24268-4 doi: |[10.1038/s41598-018-24268-4](https://doi.org/10.1038/s41598-018-24268-4) | [40] || K. M. Andersson, J. Stover, The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand, Vaccine, 29 (2011), 6092-6099. https://doi.org/10.1016/j.vaccine.2011.06.060 doi: |[10.1016/j.vaccine.2011.06.060](https://doi.org/10.1016/j.vaccine.2011.06.060) | Nagelkerke, T. B\u00e4rnighausen, R. Bakker, F. Tanser, M. L. Newell, et al., The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model, Foster, W. Rawlinson, N. Tedla, R. A. Bull, C. A. R. Bull, Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune R. Nutalai, A. Dijokaite-Guraliuc, D. Zhou, H. M. Ginn, et al., Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 Alirezaylavasani, A. Ravussin, G. Solum, T. T. Tran, et al., Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults, Nat. Commun., 13 (2022), 1-12. | | [45] || H. N. Altarawneh, H. Chemaitelly, H. H. Ayoub, M. R. Hasan, P. Coyle, H. M. Yassine, et al., Protection of SARS-CoV-2 natural infection against P. Leite, P. Casaca, E. Fernandes, C. Antunes, et al., Risk of BA.5 infection in individuals Friis, P. Bager, M. Stegger, J. Fonager, A. Fomsgaard, et al., Risk of reinfection, vaccine protection, and severity of infection with the BA.5 Omicron subvariant: A M. J. Fumagalli, N. S. Hojo-Souza, N. Salazar, G. G. Almeida, et al., Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern Graeser, S. Giese, K. Ciminski, et al., COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent "}